New hope for Hard-to-Treat ovarian cancer: drug combo trial launches

NCT ID NCT07637851

First seen Jun 12, 2026 · Last updated Jun 16, 2026 · Updated 1 time

Summary

This study tests a new drug, ubamatamab, combined with standard chemotherapy drugs (carboplatin, paclitaxel, and bevacizumab) in 43 people with advanced ovarian cancer that did not respond well to initial treatment. The goal is to see if the combination is safe and can shrink tumors. Participants will receive three cycles of the combination, then maintenance therapy for up to 15 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Centre Eugène Marquis

    Rennes, 35042, France

    Contact

  • Centre François Baclesse

    Caen, 14076, France

    Contact

  • Centre Georges François Leclerc

    Dijon, 21079, France

    Contact

  • Centre Léon Bérard

    Lyon, 69373, France

    Contact

  • Gustave Roussy

    Villejuif, 94805, France

    Contact

  • HCL - Centre Hospitalier Lyon Sud

    Pierre-Bénite, 69495, France

    Contact

  • Hôpital de Hautepierre

    Strasbourg, 67098, France

    Contact

  • ICM Val d'Aurelle

    Montpellier, 34298, France

    Contact

  • ICO - Centre René Gauducheau

    Saint-Herblain, 44805, France

    Contact

  • Institut Bergonié

    Bordeaux, 33076, France

    Contact

  • Institut Paoli Calmettes

    Marseille, 13273, France

    Contact

Conditions

Explore the condition pages connected to this study.